×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Progressive Supranuclear Palsy (PSP) Treatment Guide
therapeutic
2,777 words
KG: ent-dise-bfd8f32d
2026-03-26
kind:therapeutic
section:therapeutics
state:published
topic:psp
topic:tauopathy
Contents
Progressive Supranuclear Palsy (PSP) Treatment Guide
💊
Therapeutic Info
Name
Progressive Supranuclear Palsy (PSP) Treatment Guide
Summary
Comprehensive treatment guide for Progressive Supranuclear Palsy including pharmacological therapies, disease-modifying approaches, and multidisciplinary management
Knowledge Graph
Related Hypotheses (17)
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
Cell-Type Specific TFEB Modulation
Score: 0.48
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
APOE-Dependent Autophagy Restoration
Score: 0.61
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
APOE-TREM2 Interaction Modulation
Score: 0.48
Astrocyte-Mediated Neuronal Epigenetic Rescue
Score: 0.48
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.42
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.40
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.40
Show 12 more
Related Analyses (8)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Show 3 more
Related Experiments (30)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Show 25 more